Methods to identify patients at risk of developing adverse...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S091200, C536S023500, C536S024310

Reexamination Certificate

active

07906283

ABSTRACT:
The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.

REFERENCES:
patent: 7083921 (2006-08-01), Murphy et al.
patent: 2004/0265825 (2004-12-01), Tartakovsky
patent: 2005/0069936 (2005-03-01), Diamond et al.
patent: 2006/0160119 (2006-07-01), Turner et al.
patent: 2007/0003931 (2007-01-01), Mrazek et al.
patent: 2008/0299125 (2008-12-01), Hinds et al.
Halushka et al. Nature. Jul. 1999. 22: 239-247.
Lucentini et al. The Scientist (2004) vol. 18, p. 20.
Wacholder et al . J. Natl. Cancer Institute (2004) 96(6):434-442.
Ioannidis et al. Nature genetics (2001) 29:306-309.
Kato et al. Neuropsychobiology. 2006.53: 186-195.
Menke et al. American Journal of Psychiatry. 2008. 165(7): 917-918.
Laje et al . American Journal of Psychiatry. 2007. 164: 1530-1538.
GeneCard for the PAPLN gene available via url: <genecards.org/cgi-bin/carddisp.pl?gene=Papln&snp=299#snp>, printed on Dec. 15, 2009.
GeneCard for the IL28RA gene available via url: <genecards.org/cgi-bin/carddisp.pl?gene=II28ra&snp=284#snp>, printed on Dec. 15, 2009.
Thisted, R.A. May 25, 1998; available online via url: <stat.uchicago.edu/˜thisted>, pp. 1-6.
Laje et al. American Journal of Human Genetics. 141B, Issue 7, pp. 724-725, abstract O22.3, available online Sep. 11, 2006.
Choi et al.,Neuropsychobiology, 52, 155-162 (2005).
Lipsky et al.,Neuropsychopharmacology, 31(No. Suppl. 1), S23-S24 (2006).
McMahon,American Journal of Medical Genetics, 141B(No. 7), 689-690 (2006).
McMahon,Neuropsychopharmacology, 31(No. Suppl. 1), S38-S39 (2006).
Murphy et al.,American Journal Psychiatry, 160(10), 1830-1835 (2003).
GenBank Accession No. AAH32004 (Jul. 15, 2006).
GenBank Accession No. AAH37954 (Sep. 1, 2006).
GenBank Accession No. BC032004 (Jul. 15, 2006).
GenBank Accession No. BC037954 (Sep. 1, 2006).
GenBank Accession No. NM—000827 (Sep. 24, 2007).
GenBank Accession No. NM—000828 (Sep. 17, 2007).
GenBank Accession No. NM—000833 (Sep. 25, 2007).
GenBank Accession No. NM—001018064 (Oct. 28, 2007).
GenBank Accession No. NM—006028 (Sep. 3, 2007).
GenBank Accession No. NM—021956 (Oct. 22, 2007).
GenBank Accession No. NM—170743 (Sep. 25, 2007).
GenBank Accession No. NM—173462 (Jun. 26, 2007).
Mann et al., “ACNP Task Force report on SSRIs and suicidal behavior in youth,”Neuropsychopharmacology, 31 (3), 473-492 (2006).
McMahon et al., “Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment,”Am. J. Hum. Genet., 78, 804-814 (2006).
Rush et al., “Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design,”Control Clin. Trials, 25 (1), 119-142 (2004).
Trivedi et al., “Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice,”Am. J. Psychiatry, 163 (1), 28-40 (2006).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods to identify patients at risk of developing adverse... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to identify patients at risk of developing adverse..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to identify patients at risk of developing adverse... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2722066

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.